Skip to content

Study of efficiency and effectiveness of a new family of introcular lenses

Study of the effectiveness and efficiency of a new family of single-focal and multifocal introcular lenses under the Customized Cataract Solution project

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
REBEC
Registry ID
RBR-772s6y
Enrollment
Unknown
Registered
2020-06-04
Start date
2020-06-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unspecified senile cataract

Interventions

Participants, after fulfilling the inclusion and exclusion criteria and signing the informed consent form, will undergo clinical and complementary exams before the facectomy, 1, 2, 3, 6 and 12 months
evaluation of the state of the eye condition by the slit lamp and measurement of intraocular pressure with the Goldmann applanation tonometer. Complementary exams consist of PAM (potential acuity mete
ocular ultrasound in situations of non-visualization of the fundus resulting from lens opacification
optical and immersion biometrics for calculating the IOP dioptric power (initially only axial length eyes able to be used for calculation according to the SRK equation will be considered, in a second
retinography
optical coherence tomography.         14.1. Calculation of IOL power The study participants will be submitted to optical and ultrasonic biometrics by the immersion method to measure the axial length
Device
Procedure/surgery

Sponsors

João Marcelo de Almeida Gusmão Lyra
Lead Sponsor
MediPhacos Industrias Medicas
Collaborator

Eligibility

Age
21 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients who had a clinically documented diagnosis of age-related cataract (cortical, nuclear, sub-capsular or a combination) that was considered amenable to treatment by extraction of the cataract using the intracapsular facectomy method. Adult patients 21 years of age or older. Patients eligible for primary intraocular lens implantation. Patients willing and able to perform clinical and complementary exams for follow-up for a minimum of 1 year after cataract surgery. Patients requiring intraocular lens implantation powers ranging from 10 to 30 diopters. Patients with visual potential of 20/40 or better in the eye indicated for intraocular lens implantation. Patients with corneal cylinder to correct less than 1 diopter.

Exclusion criteria

Exclusion criteria: Patients with the best corrected visual acuity less than or equal to 20/200 in the contralateral eye. Patients with any pathology of the anterior segment in which the intracapsular facectomy procedure with primary IOL implantation is contraindicated (examples: keratoconus, corneal dystrophies or scars, anterior uveitis). Patients with corneal inflammation or edema, included and not limited to: keratitis, keratoconjunctivitis and keratitis. Patients with uncontrolled glaucoma or glaucoma under treatment. Patients with a history of retinal detachment. Patients with diabetic retinopathy (proliferative or non-proliferative). Patients with congenital, metabolic, traumatic or complicated cataracts. Patients with marked microphthalmia or aniridia. Patients who have had previous proposed eye surgery. Patients who have already received another IOL in the contralateral eye. Irregular astigmatism of the cornea. Amblyopia. Clinically significant changes in the retinal pigment epithelium / macula. Neovascularization of the iris, camerular and retinal angles. Severe recurrent inflammation of the anterior or posterior segment of unknown etiology. Optic atrophy. Patients with immunodeficiency (infectious, neoplasic or medicated) Patients on chronic use of systemic steroids or immunosuppressive drugs. Patients participating in another clinical trial simultaneously. Patients with strong dependence on intermediate vision, night vision or specific occupational requirements (examples: commercial pilots and professional drivers).

Design outcomes

Primary

MeasureTime frame
Safety assessment of the different models of the implanted IOL, observing, describing and characterizing adverse events that are directly related to the implantation of the IOL, for example: presence of inflammation, positioning of the IOL both in the immediate and late postoperative periods, displacement and decentralization IOL, presence and intensity of opacity formation in the posterior capsule, presence of macular edema after facectomy ;Evaluation of visual acuity without correction for distance and near using the Snellen table in the metric equivalent to 6 meters and high contrast, and the Jaeger table positioned 30 cm away

Secondary

MeasureTime frame
Assessment of quality of life by comparing before and after IOL implantation using the NEI VFQ-25 questionnaire validated for the Portuguese language

Countries

Brazil

Contacts

Public ContactJoão Marcelo Lyra

João Marcelo de Almeida Gusmão Lyra

joaomlyra@gmail.com+558232232478

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 6, 2026